Protagonist Therapeutics (PTGX) Work In Process (2021 - 2024)
Protagonist Therapeutics (PTGX) posted Work In Process of $165.0 million for Q4 2024, up 383620.93% sequentially from $43000.0 in Q2 2024, and up 1550.0% YoY from $10.0 million in Q1 2024.
Protagonist Therapeutics (PTGX) Work In Process (2021 - 2024) Analysis & Trends
Protagonist Therapeutics has reported Work In Process for 4 years, with the latest figure at $165.0 million in Q4 2024.
- Quarterly Work In Process rose 1550.0% year-over-year to $165.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $165.0 million (up 1550.0% YoY) and the FY2024 annual result came in at $165.0 million, up 1550.0% from the prior year.
- Work In Process advanced to $165.0 million in Q4 2024 per PTGX's latest filing, from $43000.0 in the prior quarter.
- Over five years, Work In Process peaked at $300.0 million in Q1 2024 and troughed at $10000.0 in Q4 2022.
- A 4-year average of $68.1 million and a median of $1.6 million in 2021 frame the typical range for Work In Process.
- The sharpest annual moves came in 2022 and 2023: Work In Process slumped 99.36% in 2022, then surged 99900.0% in 2023.
- Over 4 years, Work In Process stood at $1.6 million in 2021, then plunged by 99.36% to $10000.0 in 2022, then soared by 99900.0% to $10.0 million in 2023, then surged by 1550.0% to $165.0 million in 2024.
- According to Business Quant data, Work In Process over the past three periods registered $165.0 million, $43000.0, and $300.0 million for Q4 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 165.00 Mn |
| Jun 30, 2024 | 43,000.00 |
| Mar 31, 2024 | 300.04 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Dec 31, 2022 | 10,000.00 |
| Sep 30, 2022 | 125,000.00 |
| Dec 31, 2021 | 1.57 Mn |